Semaglutide peptide: what it is, what the trials measured, and research
Semaglutide is a 31-amino-acid GLP-1 receptor agonist peptide with a C18 fatty diacid side chain, studied for glycemic control, body-weight reduction and cardiovascular outcomes in the SUSTAIN, STEP and SELECT trials. PrymaLab supplies research-grade Semaglutide 5mg, 10mg, 15mg, 20mg and 30mg lyophilized vials for research use; these are not the prescription products.
- Sequence or size: 31 residues, a GLP-1(7-37) analogue with Aib8, Arg34 and a C18 fatty diacid on Lys26; 4113.6 g/mol; CAS 910463-68-2.
- Class: long-acting GLP-1 receptor agonist; albumin binding gives a half-life of about one week.
- Studied for: type 2 diabetes (SUSTAIN trials), obesity (STEP trials) and cardiovascular outcomes (SELECT); oral tablets tested separately.
- Key results in the literature: 14.9% mean weight change versus 2.4% on placebo over 68 weeks (STEP 1); a 20% relative reduction in major adverse cardiovascular events (SELECT).
- Brand products: Ozempic (2017), Wegovy (2021) and Rybelsus are prescription drugs; PrymaLab's vials are research grade, not a substitute.
- Storage: lyophilized vial frozen at -20°C or refrigerated, protected from light; reconstituted solution at 2 to 8°C.
- Forms and sizes at PrymaLab: Semaglutide 5mg, Semaglutide 10mg, Semaglutide 15mg, Semaglutide 20mg and Semaglutide 30mg vials.
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Receptors | GLP-1 only | GLP-1 and GIP |
| Size and lipid | 31 residues, C18 fatty diacid at Lys26 | 39 residues, C20 fatty diacid at Lys20 |
| Largest weight-management trial | 14.9% mean weight change at 68 weeks (STEP 1) | 20.9% at 72 weeks (SURMOUNT-1); not head to head |
| Head-to-head trial | Comparator in SURPASS-2 (1,879 adults with type 2 diabetes, 40 weeks) | All three tirzepatide arms reduced HbA1c and weight more than the semaglutide comparator |
| Forms at PrymaLab | 5mg to 30mg lyophilized vials | 5mg to 100mg lyophilized vials |
The peptide reconstitution calculator converts vial size and diluent into concentration; the how to reconstitute tirzepatide guide has worked mixing examples that apply equally to semaglutide vials.
Semaglutide is a GLP-1 receptor agonist peptide approved for type 2 diabetes (Ozempic, 2017) and chronic weight management (Wegovy, 2021), with an oral tablet (Rybelsus) developed separately. In STEP 1, semaglutide produced a 14.9% mean weight reduction over 68 weeks against 2.4% on placebo, and SELECT reported a 20% relative reduction in major cardiovascular events. This guide covers the molecule, its mechanism, what the trials measured, and the research-grade semaglutide PrymaLab supplies, which is not Ozempic, Wegovy or Rybelsus.
This guide summarises what the clinical research reports on semaglutide, the side effects recorded in trials, how it compares to tirzepatide and other GLP-1 drugs, and the safety findings, with references to peer-reviewed clinical research.
- What the drug is and how this GLP-1 receptor agonist works at the molecular level
- All FDA-approved uses — type 2 diabetes, weight management, and cardiovascular risk reduction
- Findings from the STEP, SUSTAIN and SELECT trials and what each one measured
- Semaglutide vs tirzepatide — head-to-head comparison of efficacy, cost, and safety
- Side effects, drug interactions, and contraindications reported in trials and labels
- Semaglutide before and after: how weight change was measured over time in the trials
- Frequently asked questions answered from the research
What Is Semaglutide? Understanding the GLP-1 Receptor Agonist
Understanding what semaglutide is used for begins with its origins: this medication is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone that plays a central role in blood sugar control and appetite control. Developed by Novo Nordisk, the peptide was engineered from native human GLP-1 with a few key changes that extend its half-life to about seven days.
These changes include an amino acid substitution at position 8 (alanine to alpha-aminoisobutyric acid) that resists breakdown by the enzyme dipeptidyl peptidase-4 (DPP-4), and a fatty acid chain that lets binding to albumin in the blood, slowing renal clearance.
The U.S. Food and Drug Administration (FDA) has approved this GLP-1 agonist under three distinct brand names, each targeting a specific clinical sign. Ozempic (injectable semaglutide) was approved in December 2017 for the treatment of type 2 diabetes mellitus. Wegovy (injectable semaglutide) got FDA approval in June 2021 mainly for chronic weight care in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Rybelsus (oral semaglutide) was approved in September 2019 as the first oral GLP-1 receptor agonist for type 2 diabetes.
Where Does Semaglutide Fit in the GLP-1 Drugs List?
Semaglutide belongs to the broader class of GLP-1 receptor agonists, which includes several other FDA-approved drugs. The complete GLP-1 drugs list includes exenatide (Byetta, Bydureon), liraglutide (Victoza for diabetes, Saxenda for weight loss), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and the newer dual-agonist tirzepatide (Mounjaro for diabetes, Zepbound for weight loss).
Among these, semaglutide has become one of the most widely prescribed, with large clinical trial programmes on metabolic and cardiovascular outcomes.
Key Distinction: This treatment is a GLP-1 receptor agonist, not insulin. It works by enhancing the body’s own insulin production in response to food intake, rather than replacing insulin directly. This glucose-dependent mechanism means this therapy carries a greatly lower risk of hypoglycemia compared to insulin or sulfonylurea drugs when used as monotherapy.
Native GLP-1 and its cleavage by DPP-4
The long-acting GLP-1 receptor agonists start from a hormone that barely lasts in the body. Native GLP-1 is a 30-amino acid peptide made in the endocrine L-cells of the intestine by differential processing of proglucagon, and it is released in response to meals (Holst 2007). Its main actions are to stimulate insulin secretion and to inhibit glucagon secretion, which limits the rise in glucose after eating, and it also slows gastrointestinal motility and secretion (Holst 2007).
The hormone is inactivated by dipeptidyl peptidase IV (DPP-4), which removes its first two residues. Mentlein and colleagues showed in 1993 that the purified enzyme converts GLP-1 (7-36) amide to its des-His-Ala form, that human serum produces the same fragments, and that the enzyme's kinetics allow degradation at physiological, nanomolar concentrations (Mentlein et al. 1993). Holst later described the inactivation as so fast that much of it happens before GLP-1 leaves the gut. That raised the possibility that some of its effects travel through sensory neurons in the intestine and liver, and it meant that studies had to separate measurements of intact hormone from intact hormone plus metabolites (Holst 2007). The rapid degradation of GLP-1 and GIP by DPP-4 is what led to degradation-resistant GLP-1 receptor agonists and to DPP-4 inhibitors (Baggio et al. 2007).
How semaglutide was designed
Semaglutide was developed from liraglutide, an acylated GLP-1 analogue that binds serum albumin and was already approved for diabetes and obesity (Lau et al. 2015). In their 2015 discovery paper, Lau and colleagues set out to extend its action further by raising albumin affinity and securing full stability against metabolic degradation (Lau et al. 2015). They reported that the fatty acid and the chemistry linking it to the peptide were the features that decided albumin affinity, GLP-1 receptor potency and the length of exposure (Lau et al. 2015).
The molecule they selected differs from human GLP-1 at two positions, Aib at 8 and arginine at 34, and is derivatised at lysine 26 (Lau et al. 2015). Higher albumin affinity came at a cost at the receptor: semaglutide's GLP-1 receptor affinity was 0.38 ± 0.06 nM, a threefold decrease from liraglutide (Lau et al. 2015). In mini-pigs its plasma half-life after intravenous delivery was 46.1 hours (Lau et al. 2015). These figures come from the discovery paper's own assays and from animals, and they were published while semaglutide was still in phase 3 testing, before the clinical programmes described in the rest of this guide reported (Lau et al. 2015).
How Does Semaglutide Work? Mechanism of Action Explained
Grasp how the medication works needs examining its effects on multiple organ systems simultaneously. As a GLP-1 receptor agonist, this GLP-1 receptor agonist binds to and starts GLP-1 receptors found throughout the body, triggering a cascade of body responses that collectively improve blood sugar control, reduce appetite, and promote weight loss.
Pancreatic Effects: Insulin and Glucagon Regulation
When the drug starts GLP-1 receptors on pancreatic beta cells, it increases glucose-dependent insulin secretion. This means the pancreas releases more insulin when blood sugar levels are elevated (such as after a meal) but does not overstimulate insulin production when blood sugar is normal, greatly reducing the risk of hypoglycemia.
Simultaneously, this medication suppresses glucagon secretion from pancreatic alpha cells. Glucagon is a hormone that signals the liver to release stored glucose into the bloodstream. By reducing glucagon levels, the peptide decreases hepatic glucose output, adding to lower fasting blood sugar levels and improved overall glycemic control.
Gastrointestinal Effects: Gastric Emptying and Satiety
This GLP-1 agonist greatly slows gastric emptying, the rate at which food moves from the stomach into the small intestine. This delayed gastric emptying serves two important functions. First, it reduces the rate at which glucose from food enters the bloodstream, blunting postprandial (after-meal) blood sugar spikes. Second, it prolongs the feeling of fullness after eating, which naturally reduces food intake.
Central Nervous System Effects: Appetite and Food Reward
GLP-1 receptors are also present in the hypothalamus and other brain regions that regulate appetite, hunger, and food reward. Semaglutide crosses the blood-brain barrier and directly influences these neural circuits, reducing hunger signals and decreasing the hedonic (pleasure-based) drive to eat. Functional MRI studies have shown that this injectable reduces start in brain regions linked with food craving and reward when patients are shown images of high-calorie foods.
This central appetite suppression is a key differentiator from older weight loss drugs and explains why patients report not just eating less, but genuinely wanting less food.
Research Insight: A 2023 study published in Nature Medicine showed that semaglutide’s effects on the brain’s reward centers may extend beyond food, with preliminary evidence suggesting reduced cravings for alcohol and other addictive substances. This finding has opened new research avenues for the agent’s possible uses beyond diabetes and obesity.
Semaglutide Benefits: What the Research Shows
The semaglutide benefits documented in clinical research extend well beyond its main signs of blood sugar control and weight loss. Large-scale clinical trial programs, including the SUSTAIN trials (diabetes), STEP trials (weight loss), and the landmark SELECT trial (heart outcomes), reported effects on body weight, glucose control, cardiovascular events and quality-of-life scores.
Weight Loss Benefits
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program is the most full weight loss dataset for this GLP-1 agonist. Across multiple STEP trials involving thousands of participants, semaglutide (Wegovy) showed average weight loss of 15–17% of total body weight over 68 weeks. In the STEP 1 trial, 86% of participants lost at least 5% of their body weight, 69% lost at least 10%, and 50% lost at least 15%. These results were larger than those reported for earlier approved weight loss medications.
Blood Sugar and Diabetes Control
For type 2 diabetes care, the SUSTAIN trial program reported HbA1c (a measure of average blood sugar over 2–3 months) reductions of 1.5–2.0 percentage points, depending on the trial and baseline HbA1c level. The trials also reported lower fasting plasma glucose and smaller postprandial glucose excursions.
Cardiovascular Benefits
The SELECT trial, published in the New England Journal of Medicine in 2023, was a landmark study that tested this medication in patients with established heart disease and overweight or obesity but without diabetes. The trial showed a 20% reduction in major adverse heart events (MACE), including heart attack, stroke, and heart death.
This finding led to an expanded FDA sign for Wegovy to include heart risk reduction, making semaglutide the first weight loss medication with a proven heart benefit.
Additional Metabolic Benefits
Beyond the main endpoints, clinical trials reported changes in several secondary measures. These include reductions in systolic blood pressure (4–7 mmHg on average), gains in lipid profiles (reduced triglycerides, increased HDL cholesterol), reductions in liver fat content (relevant for non-alcoholic fatty liver disease), gains in swelling markers (C-reactive protein, interleukin-6), and gains in physical functioning and quality of life scores. Emerging research also suggests possible benefits for kidney function, sleep apnea, and osteoarthritis symptoms, though these signs are still under study.
| Semaglutide Benefit | Clinical Evidence | Trial Program |
|---|---|---|
| Weight loss (15–17% body weight) | STEP 1: 86% lost ≥5%, 50% lost ≥15% | STEP 1–5 |
| HbA1c reduction (1.5–2.0%) | Superior to all comparators tested | SUSTAIN 1–10 |
| Cardiovascular risk reduction (20%) | 20% MACE reduction in SELECT trial | SELECT |
| Blood pressure reduction | 4–7 mmHg systolic reduction | STEP, SUSTAIN |
| Triglyceride improvement | 12–22% reduction | SUSTAIN |
| Liver fat reduction | Significant reduction in hepatic steatosis | Emerging data |
| Inflammatory marker reduction | CRP, IL-6 improvements | SELECT, STEP |
| Quality of life improvement | Significant improvement in SF-36 scores | STEP 1–3 |
Semaglutide for Weight Loss: Clinical Evidence and Results
Semaglutide weight loss results have been extensively documented across the STEP clinical trial program, which enrolled over 10,000 participants across multiple studies. The weight loss reported with semaglutide (Wegovy) in these trials was larger than in earlier trials of approved weight loss medications.
STEP Trial Results Summary
The STEP 1 trial enrolled 1,961 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Participants receiving semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group.
The STEP 2 trial mainly studied patients with type 2 diabetes and obesity, showing 9.6% weight loss (lower than STEP 1 due to the body effects of diabetes on weight loss). The STEP 3 trial combined the compound with intensive behavioral therapy, achieving 16.0% weight loss. The STEP 5 trial extended the treatment period to 104 weeks (2 years), confirming that weight loss was sustained with continued treatment, with participants keeping an average loss of 15.2% of body weight.
Body Composition Changes
An important consideration with any weight loss intervention is the makeup of weight lost. Dual-energy X-ray absorptiometry (DEXA) analyses from the STEP trials revealed that about 60–65% of weight lost with this injectable was fat mass, while 35–40% was lean mass. This ratio is comparable to weight loss achieved through caloric restriction alone.
Semaglutide for Type 2 Diabetes Management
The agent has become one of the most prescribed drugs for type 2 diabetes, supported by the full SUSTAIN clinical trial program. The American Diabetes Association (ADA) 2024 Standards of Care now recommend GLP-1 receptor agonists, including this treatment, as a preferred second-line therapy after metformin for most patients with type 2 diabetes, and as a first-line option for patients with set up heart disease or high heart risk.
Glycemic Control Outcomes
Across the SUSTAIN trials, this therapy showed superior HbA1c reduction compared to every active comparator tested, including sitagliptin (SUSTAIN 2), exenatide extended-release (SUSTAIN 3), insulin glargine (SUSTAIN 4), dulaglutide (SUSTAIN 7), and canagliflozin (SUSTAIN 8). In SUSTAIN 6, the heart outcomes trial, the medication also showed a 26% reduction in major adverse heart events in patients with type 2 diabetes and high heart risk.
The oral form, Rybelsus, showed comparable HbA1c reductions in the PIONEER trial program, offering an other for patients who prefer oral medication over injections.
Potential for Diabetes Remission
Some research has looked at type 2 diabetes remission. A 2024 study published in The Lancet Diabetes & Endocrinology found that 12% of patients treated with the drug achieved diabetes remission (defined as HbA1c below 6.5% without diabetes drugs) after 68 weeks, compared to 2% in the placebo group.
Cardiovascular Benefits of Semaglutide
The SELECT trial (Semaglutide Effects on Heart Outcomes in People with Overweight or Obesity) was a randomized, double-blind, placebo-controlled trial involving 17,604 participants aged 45 years or older with set up heart disease and a BMI of 27 or greater, but without diabetes.
The results, published in the New England Journal of Medicine in November 2023, showed that semaglutide reduced the composite main endpoint of heart death, nonfatal myocardial infarction, or nonfatal stroke by 20% compared to placebo (hazard ratio 0.80, 95% CI 0.72–0.90). This benefit was consistent across subgroups defined by age, sex, race, baseline BMI, and baseline heart risk factors.
The trial also showed reductions in heart failure events, all-cause mortality (though not statistically major as a standalone endpoint), and the need for coronary revascularization procedures.
Semaglutide in clinical trials: what was studied
The approved products were studied in large randomised trials in which the dose was increased gradually at the start of treatment, a design chosen to limit gastrointestinal side effects such as nausea and vomiting. The labels for Ozempic, Wegovy and Rybelsus set out regimens for those prescription products. This guide does not reproduce them, and they do not apply to research material. The trial designs and measured outcomes are summarised in the sections above and in the trial table further down.
Oral semaglutide (Rybelsus) is formulated with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), and food cuts its absorption sharply. Sublingual semaglutide, offered by some compounding pharmacies, is not FDA-approved, and its absorption can vary greatly between people; oral peptide uptake is covered in a separate guide.
⚠ Important Safety Note: Compounded semaglutide is not FDA-approved and is not subject to the same manufacturing standards as brand-name products. The FDA has issued warnings about compounded semaglutide products, including concerns about sterility, potency, and the use of salt forms (semaglutide sodium) that differ from the approved form.
Semaglutide side effects reported in trials
The side effect profile of this GLP-1 receptor agonist is well-characterized through extensive clinical trial data involving tens of thousands of participants. Most side effects are gut in nature, dose-dependent, and tend to diminish over time as the body adjusts to the medication.
Common Side Effects
- 1Nausea (40–44% of patients)
The most often reported side effect, often most pronounced during dose escalation. Usually mild to moderate and improves within 4–8 weeks.
- 2Diarrhea (30% of patients)
Often occurs during the first few weeks of treatment or after dose increases. Usually self-limiting.
- 3Vomiting (24% of patients)
More common during titration phases.
- 4Constipation (24% of patients)
Related to slowed gastric emptying.
- 5Abdominal pain (20% of patients)
Usually mild and linked with gut adjustment. Pancreatitis is listed among the serious side effects below.
- 6Headache (14% of patients)
Often related to changes in blood sugar, dehydration, or reduced caloric intake.
- 7Fatigue (11% of patients)
May be related to reduced caloric intake and body adjustment.
Serious Side Effects (Rare)
While rare, several serious side effects have been linked with the peptide and need immediate medical attention. These include acute pancreatitis (swelling of the pancreas, presenting as severe persistent abdominal pain radiating to the back), gallbladder disease (gallstones and cholecystitis, occurring in about 1.5–2.5% of patients in clinical trials), acute kidney injury (usually second to severe dehydration from vomiting or diarrhea), diabetic retinopathy complications (in patients with pre-existing diabetic eye disease), and allergic reactions (extremely rare, presenting as rash, itching, or anaphylaxis).
Semaglutide Withdrawal Symptoms
This GLP-1 agonist withdrawal symptoms are not withdrawal in the traditional pharmacological sense, as semaglutide is not addictive and does not cause physical dependence. However, discontinuing the compound can lead to a return of pre-treatment appetite levels, weight regain (studies show about two-thirds of lost weight may be regained within one year of discontinuation), worsening of blood sugar control in diabetic patients, and a psychological adjustment period as appetite and food cravings return.
Semaglutide vs Tirzepatide: Complete Comparison
The comparison of semaglutide vs tirzepatide is one of the most searched topics in weight loss and diabetes care. Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss) is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly, while semaglutide is a selective GLP-1 receptor agonist from Novo Nordisk. The table compares semaglutide with tirzepatide on the main trial measures.
| Factor | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single) | Dual GIP/GLP-1 receptor agonist |
| Average weight loss | 15–17% body weight | 20–22.5% body weight |
| HbA1c reduction | 1.5–2.0% | 2.0–2.4% |
| CV outcomes data | SELECT trial: 20% MACE reduction | SURPASS-CVOT: results pending |
| FDA approvals | Diabetes, weight loss, CV risk | Diabetes, weight loss |
| Oral formulation | Yes (Rybelsus) | In development (oral tirzepatide) |
| Real-world safety data | 7+ years (since 2017) | 3+ years (since 2022) |
| GI side effects | Nausea 40–44% | Nausea 25–33% |
| Approximate monthly cost | $900–$1,350 (brand) | $1,000–$1,200 (brand) |
The SURMOUNT-5 trial, a head-to-head comparison of tirzepatide vs semaglutide for weight loss, showed that tirzepatide produced greater weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). Semaglutide has the longer real-world safety record, cardiovascular outcome data from SELECT, and an oral form (Rybelsus).
Semaglutide vs Other GLP-1 Drugs
Beyond tirzepatide, semaglutide is often compared to other GLP-1 receptor agonists.
Liraglutide vs Semaglutide
Liraglutide (Victoza for diabetes, Saxenda for weight loss) was the first GLP-1 receptor agonist widely used for weight care. The key differences between liraglutide vs semaglutide include half-life, weight loss effect (this GLP-1 receptor agonist produces about twice the weight loss of liraglutide: 15–17% vs 5–8%), and HbA1c reduction (the drug is superior).
The SUSTAIN 10 trial compared semaglutide with liraglutide directly and found semaglutide superior for both HbA1c reduction and weight loss.
Retatrutide vs Semaglutide
Retatrutide is an investigational triple-agonist (GIP/GLP-1/glucagon receptor agonist) now in Phase 3 clinical trials. Early Phase 2 data showed notable weight loss of up to 24% at 48 weeks, possibly exceeding both this GLP-1 agonist and tirzepatide. However, retatrutide is not yet FDA-approved and its long-term safety profile is unknown. The comparison of retatrutide vs semaglutide will become more meaningful once Phase 3 trial results are available, expected in 2025–2026.
Semaglutide before and after: what the trials measured over time
The STEP trials measured body weight over 68 weeks, and the largest mean losses (15–17%) were recorded toward the end of that period. STEP 5 extended follow-up to 104 weeks and found that weight loss was sustained while treatment continued, with an average loss of 15.2% of body weight. In the STEP 1 extension, participants regained about two-thirds of the lost weight within a year of stopping. Responses varied widely between participants, and these figures are averages for a prescription product given to enrolled patients.
Other peptide classes studied in metabolic research are covered in the peptides for men overview.
Safety, Contraindications, and Drug Interactions
Semaglutide has a well-set up safety profile based on extensive clinical trial data and post-marketing surveillance. However, like all drugs, it has specific contraindications and possible drug interactions that must be considered before and during treatment.
Absolute Contraindications
This therapy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This boxed warning is based on animal studies showing that GLP-1 receptor agonists caused thyroid C-cell tumors in rodents at clinically relevant exposures. While this risk has not been confirmed in humans, the contraindication remains as a precautionary measure. The medication is also contraindicated in patients with a known hypersensitivity to this GLP-1 receptor agonist or any of its excipients.
Drug Interactions
Because the drug slows gastric emptying, it can affect the absorption of concomitantly gave oral drugs. Drugs with narrow treatment windows that depend on consistent absorption (such as warfarin, levothyroxine, and oral contraceptives) may be affected. The risk of hypoglycemia rises when semaglutide is combined with insulin or sulfonylureas.
The interaction with oral contraceptives is very important: while this GLP-1 agonist does not reduce contraceptive effect, delayed absorption may alter the timing of peak drug levels.
Special Populations
Semaglutide is not recommended during pregnancy or breastfeeding due to insufficient safety data. The label advises women of childbearing potential to use effective contraception during treatment and for at least two months after discontinuation. The compound should be used with caution in patients with a history of pancreatitis, severe gut disease (including gastroparesis), or severe renal impairment. Patients with diabetic retinopathy should be tracked closely, as rapid gains in glycemic control can temporarily worsen retinopathy.
Who are the approved products indicated for?
The prescription products are indicated for adults with type 2 diabetes (Ozempic, Rybelsus) and for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (Wegovy), whose label also covers cardiovascular risk reduction. The labels list contraindications, including a personal or family history of medullary thyroid carcinoma or MEN 2, and semaglutide is not a substitute for insulin in type 1 diabetes. These criteria apply to prescription medicines used under medical supervision. PrymaLab’s research-grade semaglutide is for laboratory research only.
What the semaglutide trials measured
The main semaglutide trials enrolled adults with obesity, type 2 diabetes or cardiovascular disease and measured body weight, glycaemic control and cardiovascular events against placebo. The table lists their populations, durations and reported results. These are results for prescription products given to enrolled patients under supervision; they are not instructions for research vials.
| Trial | Participants | Duration | Reported result |
|---|---|---|---|
| STEP 1 (Wilding and colleagues, NEJM 2021) | 1,961 adults with obesity or overweight, without diabetes | 68 weeks | 14.9% mean weight change versus 2.4% on placebo |
| STEP 2 (Davies and colleagues, Lancet 2021) | Adults with type 2 diabetes and obesity | 68 weeks | 9.6% mean weight change; the diabetes population lost less than STEP 1 |
| SUSTAIN-6 (Marso and colleagues, NEJM 2016) | 3,297 patients with type 2 diabetes at high cardiovascular risk | 104 weeks | Hazard ratio 0.74 for cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (6.6% versus 8.9%) |
| SELECT (Lincoff and colleagues, NEJM 2023) | 17,604 adults with cardiovascular disease and overweight, without diabetes | Mean follow-up 39.8 months | Hazard ratio 0.80 (6.5% versus 8.0%), a 20% relative reduction in major adverse cardiovascular events |
For research vials, concentration is the peptide mass divided by the diluent volume: a Semaglutide 5mg vial dissolved in 1 mL gives 5 mg/mL, and a Semaglutide 10mg vial in 2 mL gives the same concentration. The same arithmetic applies to the Semaglutide 15mg, Semaglutide 20mg and Semaglutide 30mg vials, and the how to reconstitute tirzepatide guide covers the same arithmetic.
Frequently Asked Questions About Semaglutide
What is semaglutide peptide?
Semaglutide is a synthetic 31-amino-acid analogue of human GLP-1 with three modifications: an Aib residue at position 8 to block DPP-4 cleavage, arginine at position 34, and a C18 fatty diacid on lysine 26 that binds albumin and stretches the half-life to about a week. It activates the GLP-1 receptor, slowing gastric emptying and reducing food intake. PrymaLab supplies it as research-grade lyophilized vials.
Is semaglutide a peptide?
Yes. At 31 amino acids it is well under the 40-residue ceiling the FDA uses to separate peptides from proteins, and its fatty acid side chain is a modification to a peptide, not a change of class. Ozempic, Wegovy and Rybelsus all contain this same peptide. Research-grade semaglutide is the molecule without the sterile formulation, dose verification or label of those products.
What did the semaglutide trials measure?
The diabetes trials (SUSTAIN) measured HbA1c, body weight and, in SUSTAIN-6, cardiovascular events. The weight-management trials (STEP) measured body weight over 68 weeks, with a 14.9% mean weight change in STEP 1 against 2.4% on placebo. SELECT measured major adverse cardiovascular events. These are results for prescription products, not instructions for research material.
Is research-grade semaglutide the same as Ozempic?
It is the same molecule but not the same product. Ozempic is a sterile, preserved solution in a dose-verified pen, manufactured under an approved New Drug Application and dispensed by prescription. Research-grade semaglutide is lyophilized powder sold by mass with a certificate of analysis, intended for laboratory use only. It is not a substitute for Ozempic, Wegovy or Rybelsus.
How is semaglutide reconstituted for research?
A lyophilized vial is dissolved in a suitable diluent, and the concentration is the peptide mass divided by the volume: a 5 mg vial in 1 mL gives 5 mg/mL, and a 10 mg vial in 2 mL gives the same concentration. The diluent is added slowly down the glass and the vial swirled, not shaken, then refrigerated at 2 to 8°C and protected from light.
How long does it take for semaglutide to work?
In the STEP trials, body weight was measured over 68 weeks, and the largest mean losses were recorded toward the end of that period. Effects on appetite and blood glucose were reported earlier, in the first weeks of treatment. These are trial averages for a prescription product.
How long do semaglutide side effects last?
Most semaglutide side effects, very nausea, vomiting, and diarrhea, are most pronounced during the first four to eight weeks of treatment and during dose escalation periods. These gut side effects became less frequent over time in the trials, and the gradual dose increase at the start of treatment was designed to limit them.
Does semaglutide make you tired?
Semaglutide-related fatigue is reported by about 11% of users, very during the first weeks of treatment and dose escalation phases. This tiredness is often related to reduced caloric intake and body adjustment rather than a direct pharmacological effect of the medication.
How long does it take for semaglutide to suppress appetite?
In trials, effects on appetite were reported within the first one to two weeks of treatment and grew as the dose was increased during the escalation period.
Why does weight change on semaglutide vary?
Responses varied widely between trial participants. Diet and physical activity affect the energy balance, and underlying medical conditions such as hypothyroidism or polycystic ovary syndrome can impair weight loss.
Certain drugs (antidepressants, corticosteroids, beta-blockers) can promote weight gain. Individual variation means some people respond more slowly.
How long does semaglutide stay in the body?
The peptide has a half-life of about seven days. After discontinuation, it takes about five to seven weeks (five half-lives) for this GLP-1 agonist to be fully removed from the body. During this washout period, the effects on appetite and blood sugar gradually diminish. This long half-life is also why side effects may persist for several weeks after stopping the medication.
Does semaglutide need to be refrigerated?
Research-grade semaglutide is a lyophilized powder, stored frozen at -20°C or refrigerated and protected from light; once dissolved, the solution is kept at 2 to 8°C. The approved pens have their own storage conditions on their labels.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist that targets one incretin pathway, while tirzepatide is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously. Clinical trials suggest tirzepatide may produce slightly greater weight loss (up to 22.5% vs 15–17% for semaglutide) and HbA1c reduction. However, semaglutide has longer real-world safety data (7+ years), proven heart outcomes from the SELECT trial, an available oral form (Rybelsus), and broader insurance coverage.
Does alcohol interact with semaglutide?
Alcohol is not an absolute contraindication. It can add to gastrointestinal side effects such as nausea and vomiting, and it can lower blood sugar, which raises the risk of hypoglycemia in diabetic patients taking insulin or sulfonylureas.
What happens to weight after semaglutide is stopped?
In the STEP 1 extension, most participants regained a major portion of the lost weight (about two-thirds) within one year of stopping. STEP 5 found that weight loss was sustained over 104 weeks while treatment continued.
Does semaglutide cause headaches?
Headaches are a reported side effect of this GLP-1 receptor agonist, occurring in about 14% of patients in clinical trials. These headaches are most common during the first weeks of treatment and during dose escalation periods. They are often related to changes in blood sugar levels, dehydration from reduced fluid intake, or the body adjusting to lower caloric intake.
⚕️ Medical Disclaimer: This article is for informational and educational purposes only. The data provided is not intended to diagnose, treat, cure, or prevent any disease or health condition. Semaglutide in its approved forms is a prescription medicine. PrymaLab’s research-grade semaglutide is for laboratory research only and is not for human use. The clinical trial data cited in this article represents average outcomes and may not reflect personal experiences.
Key Takeaways
- Semaglutide is an FDA-approved GLP-1 receptor agonist available as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral) that works by mimicking the incretin hormone GLP-1
- Clinical trials demonstrate average weight loss of 15–17% of body weight with semaglutide (Wegovy), with 50% of participants losing 15% or more in the STEP 1 trial
- The SELECT trial proved a 20% reduction in major cardiovascular events, making Wegovy the first weight loss medication with proven cardiovascular benefit
- Common side effects include nausea (40–44%), diarrhea (30%), vomiting (24%), and constipation (24%), which typically improve within 4–8 weeks
- Semaglutide vs tirzepatide: tirzepatide may produce greater weight loss (20–22.5% vs 15–17%), but the compound has longer safety data, proven CV outcomes, and an oral formulation
- This injectable is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
- Weight loss is typically sustained with continued treatment but most participants regained weight after discontinuation
- PrymaLab’s research-grade semaglutide is for laboratory research only and is not Ozempic, Wegovy or Rybelsus
PrymaLab offers research-grade peptides for laboratory research, including GLP-1 analogs, BPC-157, TB-500, and more. Every lot is tested in PrymaLab’s own laboratory (RP-HPLC purity, LC-MS identity), and certificates can be checked on the certificate verification page.
Browse Peptide Products →Related reading
- Cagrilintide and CagriSema: mechanism, trial data and safety
- Tesofensine: trials, half-life and approval status
References & Sources
- Wilding, J.P.H., et al. (2021). “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 384(11), 989–1002. doi:10.1056/NEJMoa2032183
- Lincoff, A.M., et al. (2023). “This treatment and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine, 389(24), 2221–2232. doi:10.1056/NEJMoa2307563
- Marso, S.P., et al. (2016). “This therapy and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” New England Journal of Medicine, 375(19), 1834–1844. doi:10.1056/NEJMoa1607141
- Rubino, D., et al. (2021). “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance.” JAMA, 325(14), 1414–1425. doi:10.1001/jama.2021.3224
- Davies, M., et al. (2021). “The medication 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2).” The Lancet, 397(10278), 971–984. doi:10.1016/S0140-6736(21)00213-0
- Wadden, T.A., et al. (2021). “Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy (STEP 3).” JAMA, 325(14), 1403–1413. doi:10.1001/jama.2021.1831
- Garvey, W.T., et al. (2022). “Two-Year Effects of This GLP-1 receptor agonist in Adults with Overweight or Obesity (STEP 5).” Nature Medicine, 28, 2083–2091. doi:10.1038/s41591-022-02026-4
- Jastreboff, A.M., et al. (2024). “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” New England Journal of Medicine, 389(6), 514–526. doi:10.1056/NEJMoa2301972
- Aroda, V.R., et al. (2019). “PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide.” Diabetes Care, 42(9), 1724–1732. doi:10.2337/dc19-0749
- U.S. Food and Drug Administration. (2024). “FDA Approves New Indication for Chronic Weight Management Drug.” fda.gov
- American Diabetes Association. (2024). “Standards of Care in Diabetes — 2024.” Diabetes Care, 47(Supplement 1). doi:10.2337/dc24-SINT
- Novo Nordisk. (2024). “Wegovy (semaglutide) Prescribing Information.” novo-pi.com
Michael Phelps
Marketing Director & Peptide Research Specialist at PrymaLab
Michael is an Air Force veteran with a specialized background in biochemistry and over 10 years of experience in the biotech industry. He applies military-grade precision to research standards and quality control, bridging the gap between complex scientific studies and practical use. Michael provides accurate, science-backed data on peptide research, body health, and regrowth medicine.
